动脉粥样硬化性肾动脉狭窄的治疗学进展

摘要

Atherosclerotic renal artery stenosis (ARAS) is relatively common in older patients and is often associated with presence of diabetes,dyslipidemia,coronary artery disease and peripheral arterial disease.It can cause renovascular hypertension and/or ischemic nephropathy.Major contemporary clinical trials have failed to show statistically significant benefit of revascularization over medical treatment,so the optimal management of ARAS and the patients who can benefit from revascularization remain topics of great controversy.This review summarized the advances in the therapeutics of ARAS.%动脉粥样硬化性肾动脉狭窄(atherosclerotic renal artery stenosis,ARAS)多见于老年人,常伴发糖尿病、血脂异常、冠状动脉疾病和外周血管疾病,可引起肾血管性高血压和/或缺血性肾病.目前很多大型临床试验显示介入治疗与药物治疗相比并无显著的优势,如何合理选择治疗方案以及哪些患者能从介入治疗中获益仍然是临床争议的热点,本文就近年来ARAS的治疗学进展进行综述.